MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM) - Seite 2
The Company expects to receive the results of this study in the fourth quarter of 2014.
About Human Metabolome Technologies America
Human Metabolome Technologies (HMT) is a Japan-based biotechnology company developing capillary electrophoresis mass spectrometry
(CE-MS) based metabolomics technologies and solutions to drive drug discovery, diagnosis, and food production. HMT can identify more than 1,000 species of metabolites by the metabolome analysis
technology using CE-MS. In addition, HMT has developed an original software analysis platform along with the measuring technologies, such as CE-MS, LC-MS, and MS/MS, for the realization of
metabolome analysis.
About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve
muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural
myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health
benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle
mass. To discover why MYOS is known as "The Muscle Company™," visit www.myoscorp.com.
The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Lesen Sie auch
Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of
Fortetropin™ and its effects on myostatin inhibition, including our research and development activities described herein, product and customer demand, the continued growth of repeat
purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including
the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value,
the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic
conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply
with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other
factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after
the date on which such statement is made except as required by law.